The sofosbuvir and velpatasvir fixed-dose combination was approved for the treatment of HCV infection of all six genotypes consisting of 400 mg sofosbuvir and 100 mg velpatasvir
McHutchison, Brian Pearlman, Mitchell Shiffman Trevor Hawkins, Michael Curry, Ira Jacobson Show 3 others Show less Eight weeks of sofosbuvir-velpatasvir plus GS-9857 was safe and effective for treatment-naïve
, velpatasvir, in clinical trials for COVID-19 should
Once-daily sofosbuvir-velpatasvir for 12 weeks provided high rates of sustained virologic response among both previously treated and untreated patients infected with HCV genotype 1, 2, 4, 5, or 6, including those with compensated cirrhosis
otide polymerase inhibitor sofosbuvir, the NS5A inhibitor velpatasvir, and the NS3/4A protease inhibitor GS-9857 in these patients
It also works for hepatitis C in those who also have cirrhosis or HIV/AIDS
Efficacy of the Combination of Sofosbuvir, Velpatasvir, and the NS3/4A Protease Inhibitor GS-9857 in Treatment-Naïve or Previously Treated Patients With Hepatitis C Virus Genotype 1 or 3 Infections
Study Title: A Phase 3, Global, Multicenter, Randomized, Open-Label Study to Investigate the Safety and Efficacy of Sofosbuvir/Velpatasvir/GS-9857 Fixed-Dose Combination for 8 Weeks Compared to Sofosbuvir/Velpatasvir for 12 Weeks in Direct-Acting Antiviral-Naive Subjects with Chronic HCV Infection